Table 3. Hazard ratios for overall survival, time to progression and TEE by Hb-initiation level or maximum-achieved Hb level in long-term follow-up studies.
| Overall survival | Time to progression | |||||
|---|---|---|---|---|---|---|
| Patient subgroup Hb-initiation level | Number of patients | Hazard ratio (95% CI) | P-valuea | Number of patients | Hazard ratio (95% CI) | P-valuea |
| Long-term follow-up studies | ||||||
| All patients | 1227 | 1.13 (0.98; 1.31) | 0.082 | 884 | 1.13 (0.95; 1.34) | 0.165 |
| ⩽10 g dl−1 | 393 | 0.91 (0.72; 1.16) | 114 | 0.59 (0.36; 0.96) | ||
| ⩽11 g dl−1 | 612 | 1.03 (0.85; 1.25) | 285 | 0.85 (0.64; 1.13) | ||
| >11 g dl−1 | 611 | 1.24 (1.00; 1.53) | 595 | 1.30 (1.05; 1.61) | ||
| Maximum Hb value | ||||||
| Long-term follow-up studies | ||||||
| All patients | 1227 | 1.13 (0.98; 1.31) | 0.082 | 884 | 1.13 (0.95; 1.34) | 0.165 |
| <10 g dl−1 | 64 | 1.71 (0.97; 3.02) | 16 | 10.17 (0.99; 104.36) | ||
| 10–<11 g dl−1 | 163 | 2.09 (1.42; 3.08) | 60 | 2.37 (1.01; 5.57) | ||
| 11–<12 g dl−1 | 352 | 1.89 (1.45; 2.46) | 166 | 1.85 (1.14; 2.98) | ||
| 12–13 g dl−1 | 259 | 1.59 (1.15; 2.23) | 191 | 1.75 (1.13; 2.69) | ||
| >13 g dl−1 | 599 | 1.50 (1.16; 1.94) | 511 | 1.83 (1.39; 2.41) | ||
aHR P-value (Wald test).